NCT01578564View on ClinicalTrials.gov

Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

March 31, 2016

Conditions
Cancer
Interventions
DRUG

SOR-C13

Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period

Trial Locations (3)

77230-1402

MD Anderson Cancer Center, Houston

L8V 5C2

Juravinski Cancer Center, Hamilton

N6A 4L6

London Health Sciences Centre, London

All Listed Sponsors
lead

Soricimed Biopharma Inc

INDUSTRY

NCT01578564 - Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel | Biotech Hunter | Biotech Hunter